ArticleFrontiers in medicine2026
Case report: Two cases of juxtapapillary retinal capillary hemangioma treated with intraocular cryotherapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Juxtapapillary retinal capillary hemangioma (JRCH) is a rare vascular tumor arising from or adjacent to the optic disc and may cause visual impairment due to exudation and vitreoretinal interface complications. Its management remains challenging because of the risk of optic nerve damage and the lack of standardized treatment protocols. Cryotherapy is commonly applied transsclerally for peripheral retinal capillary hemangioma (RCH) but has been rarely used for JRCH. Reports of intraocular cryotherapy are even more limited. Case presentation: We report two pediatric cases of isolated JRCH with an endophytic growth pattern. The first case involved a 6-year-old girl presenting with JRCH complicated by exudative retinal detachment. She showed a limited response to repeated laser photocoagulation and intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, and underwent pars plana vitrectomy (PPV) to relieve vitreoretinal traction. However, peripapillary vascular dilation and exudation persisted. She subsequently underwent intraocular cryotherapy, resulting in tumor regression and reduced exudation, with stable disease maintained during follow-up. The second case involved a 10-year-old girl presenting with JRCH complicated by macular edema and significant vitreoretinal traction. She underwent PPV, epiretinal membrane peeling, and intraocular cryotherapy. The tumor demonstrated a similarly favorable response to intraocular cryotherapy. Conclusion: Anatomical stabilization was observed during the available follow-up period after treatment including intraocular cryotherapy. These cases provide preliminary clinical experience with intraocular cryotherapy for the management of complex JRCH. Further studies are needed to evaluate its safety, efficacy, and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.